Related Experiment Videos
[Endothelin-1 receptor antagonists in heart failure]
P de Groote1, N Lamblin, C Bauters
1Service de cardiologie C, Hôpital cardiologique, CHRU, bd du Pr J. Leclercq, 59037 Lille, France. pdegroote@chru-lille.fr
Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 5, 2003
Summary
Endothelin-1 antagonists show promise in heart failure by improving hemodynamics. However, clinical trials with bosentan yielded disappointing results, halting further development of this drug class.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
Context:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide implicated in heart failure pathophysiology.
- ET-1 exerts its effects via two receptors: Type A (ET_A) for vasoconstriction and Type B (ET_B) for vasodilation and clearance.
- Animal models suggest ET_A antagonists offer hemodynamic and clinical benefits in heart failure.
Purpose:
- To evaluate the therapeutic potential of endothelin receptor antagonists in heart failure.
- To assess the clinical efficacy of ET-1 antagonism beyond preliminary hemodynamic improvements.
Summary:
- Preclinical studies in animal models demonstrated positive hemodynamic and clinical effects of endothelin receptor antagonists.
- Early human studies confirmed beneficial hemodynamic changes, including reduced pulmonary pressures and vascular resistance, with increased cardiac output.
- However, a large clinical trial using the oral mixed antagonist bosentan showed no significant improvement in morbidity and mortality compared to placebo.
Impact:
- The disappointing clinical outcomes have significantly impeded the development of endothelin receptor antagonists as a heart failure therapy.
- This highlights a critical disconnect between preclinical promise and clinical efficacy for ET-1 targeted therapies.
- Further research may be needed to identify specific patient populations or alternative therapeutic strategies targeting the endothelin system.